Cargando…
Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma
BACKGROUND: Thrombosis is one of the complications in the clinical course of multiple myeloma (MM). Vascular endothelial cells and/or the hemostatic-coagulatory system are thought to play an important role in thrombosis of MM. In addition to melphalan-prednisone (Mel-P) therapy, several new therapeu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783022/ https://www.ncbi.nlm.nih.gov/pubmed/29403323 http://dx.doi.org/10.2147/JBM.S147743 |
_version_ | 1783295229599678464 |
---|---|
author | Nomura, Shosaku Ito, Tomoki Yoshimura, Hideaki Hotta, Masaaki Nakanishi, Takahisa Fujita, Shinya Nakaya, Aya Satake, Atsushi Ishii, Kazuyoshi |
author_facet | Nomura, Shosaku Ito, Tomoki Yoshimura, Hideaki Hotta, Masaaki Nakanishi, Takahisa Fujita, Shinya Nakaya, Aya Satake, Atsushi Ishii, Kazuyoshi |
author_sort | Nomura, Shosaku |
collection | PubMed |
description | BACKGROUND: Thrombosis is one of the complications in the clinical course of multiple myeloma (MM). Vascular endothelial cells and/or the hemostatic-coagulatory system are thought to play an important role in thrombosis of MM. In addition to melphalan-prednisone (Mel-P) therapy, several new therapeutic drugs such as lenalidomide or bortezomib have been developed and show effectiveness against MM. However, these new drugs also have risk of therapy-related thrombosis. METHODS: We assessed 103 MM patients and 30 healthy controls, using enzyme-linked immunosorbent assays to evaluate five biomarkers: platelet-derived microparticles (PDMP), plasminogen activator inhibitor-1 (PAI-1), high mobility group box protein-1 (HMGB1), endothelial protein C receptor (EPCR), and soluble vascular cell adhesion molecule-1 (sVCAM-1). The effects of Mel-P, bortezomib, and lenalidomide on the plasma concentrations of these biomarkers were investigated. RESULTS: The plasma concentrations of PDMP, PAI-1, HMGB1, EPCR, and sVCAM-1 were higher in MM patients than in healthy controls. Mel-P, bortezomib, and lenalidomide therapies all reduced biomarker levels after treatment. However, when only patients with higher levels of EPCR were compared, differences were seen between the three therapies in the elevation of PDMP, HMGB1, and PAI-1. CONCLUSION: These results suggest that both MM and therapies for MM can induce a hypercoagulable state. The elevated risk of thrombosis conferred by hypercoagulability increases patient morbidity and mortality. Attention should be paid to therapy-related thrombosis when new therapeutic regimens are selected for MM patients. |
format | Online Article Text |
id | pubmed-5783022 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57830222018-02-05 Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma Nomura, Shosaku Ito, Tomoki Yoshimura, Hideaki Hotta, Masaaki Nakanishi, Takahisa Fujita, Shinya Nakaya, Aya Satake, Atsushi Ishii, Kazuyoshi J Blood Med Original Research BACKGROUND: Thrombosis is one of the complications in the clinical course of multiple myeloma (MM). Vascular endothelial cells and/or the hemostatic-coagulatory system are thought to play an important role in thrombosis of MM. In addition to melphalan-prednisone (Mel-P) therapy, several new therapeutic drugs such as lenalidomide or bortezomib have been developed and show effectiveness against MM. However, these new drugs also have risk of therapy-related thrombosis. METHODS: We assessed 103 MM patients and 30 healthy controls, using enzyme-linked immunosorbent assays to evaluate five biomarkers: platelet-derived microparticles (PDMP), plasminogen activator inhibitor-1 (PAI-1), high mobility group box protein-1 (HMGB1), endothelial protein C receptor (EPCR), and soluble vascular cell adhesion molecule-1 (sVCAM-1). The effects of Mel-P, bortezomib, and lenalidomide on the plasma concentrations of these biomarkers were investigated. RESULTS: The plasma concentrations of PDMP, PAI-1, HMGB1, EPCR, and sVCAM-1 were higher in MM patients than in healthy controls. Mel-P, bortezomib, and lenalidomide therapies all reduced biomarker levels after treatment. However, when only patients with higher levels of EPCR were compared, differences were seen between the three therapies in the elevation of PDMP, HMGB1, and PAI-1. CONCLUSION: These results suggest that both MM and therapies for MM can induce a hypercoagulable state. The elevated risk of thrombosis conferred by hypercoagulability increases patient morbidity and mortality. Attention should be paid to therapy-related thrombosis when new therapeutic regimens are selected for MM patients. Dove Medical Press 2018-01-19 /pmc/articles/PMC5783022/ /pubmed/29403323 http://dx.doi.org/10.2147/JBM.S147743 Text en © 2018 Nomura et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Nomura, Shosaku Ito, Tomoki Yoshimura, Hideaki Hotta, Masaaki Nakanishi, Takahisa Fujita, Shinya Nakaya, Aya Satake, Atsushi Ishii, Kazuyoshi Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title_full | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title_fullStr | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title_full_unstemmed | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title_short | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
title_sort | evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783022/ https://www.ncbi.nlm.nih.gov/pubmed/29403323 http://dx.doi.org/10.2147/JBM.S147743 |
work_keys_str_mv | AT nomurashosaku evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT itotomoki evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT yoshimurahideaki evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT hottamasaaki evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT nakanishitakahisa evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT fujitashinya evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT nakayaaya evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT satakeatsushi evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma AT ishiikazuyoshi evaluationofthrombosisrelatedbiomarkersbeforeandaftertherapyinpatientswithmultiplemyeloma |